Chimerix (CMRX) Misses Q3 EPS by 11c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Chimerix (CMRX) Misses Q3 EPS by 11c

Chimerix Announces Third Quarter 2015 Financial Results

November 5, 2015 7:30 AM EST

Topline Data from SUPPRESS Trial of Brincidofovir for Prevention of Cytomegalovirus in Hematopoietic Cell Transplant Recipients Anticipated in Early 2016

Dosing Initiated in Phase 3 SUSTAIN and SURPASS Trials of Brincidofovir for Prevention of Cytomegalovirus Disease in Kidney Transplant Recipients

DURHAM, N.C., Nov. 5, 2015 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company developing novel, oral antivirals to address unmet medical needs, today reported financial results and provided a corporate update for the third quarter of 2015.

M. Michelle Berrey, MD, MPH, President and CEO, said, "We continue to... More